The strong early efficacy data across multiple tumor types, including in KRASi-experienced patients, significantly de-risks darlifarnib as a combination partner. Traders should watch for the ASCO presentation on May 30 and the investor event on June 3 for further details and potential partnership or development updates. The stock may see positive momentum, but given the early stage, volatility around these events is expected.
Price Chart
Executive Summary
Kura Oncology reported positive first-in-human Phase 1a data for darlifarnib plus adagrasib in KRAS G12C-mutated solid tumors, showing tumor shrinkage in 77% of evaluable patients and ORRs of 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC. The data provide clinical proof-of-mechanism for targeting the mTORC1-RHEB resistance pathway, positioning darlifarnib as a potential combination partner for KRAS inhibitors. The results are being presented at ASCO 2026 and a virtual investor event is scheduled for June 3.
Key Facts
- Tumor shrinkage observed in 77% (20/26) of response-evaluable patients across PDAC, NSCLC, and CRC.
- ORR of 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC.
- Clinical activity seen in heavily pretreated patients, including those with prior KRAS inhibitor exposure.
- Combination was well tolerated with a manageable safety profile; 37% of patients remained on study at data cutoff (March 25, 2026).
- Data to be presented at ASCO 2026 on May 30; virtual investor event on June 3, 2026.
Financial Impact
No financial figures provided; early-stage clinical data with no revenue or guidance impact.
Risk Factors
- Phase 1a data is early-stage; larger trials may not replicate these results.
- Competition from other KRAS inhibitor combinations and resistance mechanisms.
- Darlifarnib 8 mg dose discontinued in this combination, indicating dose-limiting toxicity or lack of benefit at that level.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300885 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access